Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Levi & Korsinsky has notified investors that it has commenced an investigation into Immutep Limited (NASDAQ:IMMP) regarding potential violations of the federal securities laws.
On January 30, 2026, Immutep filed a Form 6-K with the SEC stating that the TACTI-004 futility analysis was “on track for the first quarter of CY2026,” citing “strong operational progress” for the trial. The filing did not reference negative efficacy signals, enrollment difficulties, or data trends that could compromise the trial’s primary endpoints.
Six weeks later, on March 13, 2026, the Independent Data Monitoring Committee (IDMC) announced that the interim futility analysis indicated the drug was unlikely to succeed and recommended stopping the study. TACTI-004 was described as Immutep’s lead oncology asset.
The January 30 filing presented the futility analysis as a forward milestone still approaching. The March 13 announcement indicated the analysis had concluded and the result was negative. The discrepancy between the earlier guidance and the eventual outcome contributed to shares falling by as much as 90% in a single session.
Levi & Korsinsky said it is inviting investors who suffered losses on Immutep securities to explore a potential recovery under the federal securities laws.

Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…